Skip to main content

Table 2 Alterations in microarchitectural properties of trabecular bone of the femur distal metaphysis.

From: Soy isoflavones avert chronic inflammation-induced bone loss and vascular disease

Treatment BV/TV (%)A TbN (1/mm3)B TbSp (mm)C TbTh (mm)D Conn Den (1/mm3)E SMIF Linear Attenuation
0 IF Placebo 8.80 ± 0.01a 3.89 ± 0.15a, c 0.27 ± 0.01a 0.051 ± 0.001 58.97 ± 8.14a 2.63 ± 0.10 1.01 ± 0.02
0 IF LPS 6.34 ± 0.01b 3.25 ± 0.15b 0.32 ± 0.01b, d 0.052 ± 0.001 40.56 ± 8.80a, b 2.83 ± 0.15 0.90 ± 0.06
126 IF Placebo 8.80 ± 0.01a 3.92 ± 0.10a 0.26 ± 0.01a 0.050 ± 0.002 47.33 ± 6.72a, b 2.91 ± 0.16 1.01 ± 0.02
126 IF LPS 6.52 ± 0.01b 3.41 ± 0.13b, e 0.30 ± 0.01b, c, d 0.050 ± 0.001 33.56 ± 3.80b 3.02 ± 0.05 0.95 ± 0.02
504 IF Placebo 7.14 ± 0.01a, b 3.50 ± 0.17b, c, d 0.29 ± 0.02a, d 0.050 ± 0.001 34.12 ± 4.99b 2.96 ± 0.14 0.96 ± 0.03
504 IF LPS 8.40 ± 0.01a, b 3.71 ± 0.14a, d, e 0.28 ± 0.01a, c 0.053 ± 0.002 52.12 ± 8.87a, b 2.93 ± 0.15 1.00 ± 0.02
P value        
LPS 0.0731 0.0085 0.119 0.2834 0.4317 0.3779 0.1018
IF 0.9681 0.7839 0.5918 0.2478 0.4208 0.1493 0.6326
LPS*IF 0.0397 0.0099 0.0124 0.6706 0.0341 0.6773 0.0613
  1. Mice were fed soy isoflavones (IF; 0, 126 or 504 mg aglycone equivalents of IF/kg diet) for 14-days prior to and during a 30-day exposure to LPS (1.33 μg/d). Results are expressed as means ± standard error. (A) trabecular bone volume (BV/TV), (B) trabecular number (TbN), (C) trabecular separation (TbSp), and (D) trabecular thickness (TbTh), (E) Connective Density (Conn Den), (F) Structure Model Index (SMI). Values for a given parameter that share the same superscript letter are not statistically different (P > 0.05) from each other.